The intricate connection between neuropharmacology and neurodegenerative diseases is becoming increasingly apparent as research delves deeper into the intricacies of the nervous system. With the approach of Alzheimer's 2024, the upcoming scientific session on this topic holds great promise for revealing innovative therapeutic approaches and gaining insights into the fundamental mechanisms contributing to neurodegeneration.
Central to this discourse is the exploration of pharmacological agents targeting specific molecular pathways associated with Alzheimer's disease. The development of drugs that influence neurotransmitter systems, regulate protein aggregation, and enhance neuroprotective mechanisms carries the potential to arrest or even reverse the progression of this devastating disorder.
The scientific session on neuropharmacology and neurodegenerative diseases at Alzheimer's 2024 is set to be a crucial platform for exchanging groundbreaking discoveries, fostering collaborations, and propelling progress towards effective treatments for Alzheimer's disease and other neurodegenerative conditions.
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
